Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference
Regeneron will participate on the "Replacing the Mainstay with Newer and Better Agents" panel on Wednesday, December 10 at 4:30 p.m. Eastern Time. The panel discussion will be broadcast live and may be accessed through the Company's web site (regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the panel discussion. An archived version will be available after the live webcast through January 9, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site at regeneron.com.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
CONTACT: Regeneron Pharmaceuticals, Inc.
Investor Relations
914-345-7640
invest@regeneron.com
or
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Kelly Hershkowitz, 212-845-5624
khershkowitz@biosector2.com
Source: Regeneron Pharmaceuticals, Inc.